XML 33 R25.htm IDEA: XBRL DOCUMENT
v3.24.3

SHAREHOLDERS' EQUITY | 9 Months Ended
--- | ---
Sep. 30, 2024
Equity [Abstract] |
SHAREHOLDERS' EQUITY | 14. SHAREHOLDERS’ EQUITY: Preferred Stock The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 5,000,000 shares of $0.01 par value preferred stock with designations, rights and preferences determined from time-to-time by the Company’s Board of Directors. Accordingly, the Company’s Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of shareholders of the Company’s common stock. In 1995, the Company issued 200,000 shares of Series A Nonconvertible Preferred Stock (Series A) to American Biomimetics Corporation (ABC) pursuant to a certain Technology Transfer Agreement between the Company and ABC. The Series A shares have a liquidation value of $7.50 per share. Series A shareholders, as a single class, have the right to elect two members of the Company’s Board of Directors. This right has never been exercised. Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote. The Series A shareholders are not entitled to any dividends. As of September 30, 2024, the Company had issued 200,000 shares of preferred stock, all of which were outstanding. Common Stock The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 200,000,000 shares of $0.01 par value common stock. Each share of the Company’s common stock entitles the holder to one vote on all matters to be voted upon by the shareholders. As of September 30, 2024, the Company had issued 48,826,922 shares of common stock, of which 47,461,274 were outstanding. During the three and nine months ended September 30, 2024 and 2023, the Company repurchased no shares of common stock. Dividends During the three months ended September 30, 2024, the Company declared and paid cash dividends of $0.40 per common share, or $19.2 million, and during the nine months ended September 30, 2024, the Company declared and paid cash dividends of $1.20 per common share, or $57.8 million, on the Company’s outstanding common stock. On October 29, 2024, the Company’s Board of Directors declared a fourth quarter dividend of $0.40 per share to be paid on December 31, 2024 to all shareholders of record of the Company’s common stock as of the close of business on December 17, 2024. All future dividends will be subject to the approval of the Company’s Board of Directors.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration